Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xeroderma pigmentosum, group F
|
31 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.020 | 1.000 | 2 | 2013 | 2016 | |||||
Xeroderma Pigmentosum, Complementation Group D
|
111 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
82 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.020 | 1.000 | 2 | 2013 | 2016 | |||||
Well Differentiated Oligodendroglioma
|
22 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Uterine Fibroids
|
154 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Undifferentiated carcinoma
|
8 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1.000 | 1 | 2003 | 2003 | |||||
Ulcerative Colitis
|
827 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.030 | 1.000 | 3 | 2007 | 2017 | |||||
Triple-Negative Breast Carcinoma
|
96 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1 | 2019 | 2019 | ||||||
Triple Negative Breast Neoplasms
|
99 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1 | 2019 | 2019 | ||||||
Treatment related acute myeloid leukaemia
|
4 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||
Transitional cell carcinoma of bladder
|
158 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||
Transient Ischemic Attack
|
16 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Thyroid Neoplasm
|
135 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.020 | 0.500 | 2 | 2014 | 2015 | |||||
Thyroid carcinoma
|
145 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.030 | 0.667 | 3 | 2014 | 2015 | |||||
Stomach Carcinoma
|
652 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.100 | 0.900 | 10 | 2009 | 2015 | |||||
Steroid Sulfatase Deficiency Disease
|
5 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||
Stage IV Gallbladder Cancer AJCC v8
|
56 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.020 | 1.000 | 2 | 2007 | 2009 | |||||
Stage III Gallbladder Cancer AJCC v8
|
56 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.020 | 1.000 | 2 | 2007 | 2009 | |||||
Stage IIB Gallbladder Cancer AJCC v8
|
56 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.020 | 1.000 | 2 | 2007 | 2009 | |||||
Stage IIA Gallbladder Cancer AJCC v8
|
56 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.020 | 1.000 | 2 | 2007 | 2009 | |||||
Stage 0 Gallbladder Cancer AJCC v8
|
56 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.020 | 1.000 | 2 | 2007 | 2009 | |||||
Squamous intraepithelial lesion
|
8 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Squamous cell carcinoma of the head and neck
|
348 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.050 | 0.400 | 5 | 2007 | 2015 | |||||
Squamous cell carcinoma of lung
|
283 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.010 | 1.000 | 1 | 2007 | 2007 | |||||
Squamous cell carcinoma of esophagus
|
329 | 0.426 | 0.800 | 17 | 7676154 | missense variant | G/C;T | snv | 0.67 | 0.070 | 1.000 | 7 | 2003 | 2017 |